The EMA has suggested that the safety information be updated for HRT, to reflect a higher risk of breast cancer and recommends new measures for the handling of leuprorelin depot medicines.
List view / Grid view
Filter the results
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
After a review of cyproterone, the EMA has recommended that the drug only be prescribed once other treatment options have failed, due to an increased meningioma risk.
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for various approvals at its January 2020 meeting; with ten drugs receiving marketing authorisation recommendations and five receiving positive opinions for specific treatments.
A Phase III study of oral relugolix has met its primary efficacy endpoint in men with advanced prostate cancer, supporting a New Drug Application submission to the FDA.
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.
A Phase III clinical trial has shown that metastatic prostate cancer improved through the use of a combination therapy with enzalutamide...
Erleada (apalutamide) has been approved for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
A clinical trial could be the world's first to look at personalised medicine in prostate cancer, with patients taking a therapy based on their DNA markers...
A minimally invasive hydrogel technology was administered, and has previously shown to decrease treatment side effects...
Researchers believe the combination with established treatment could improve outcomes in prostate cancer...
A test of contrast-enhanced subharmonic imaging has shown promise in detecting prostate cancers that were not identified by MRI...